Title : Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy.

Pub. Date : 2006

PMID : 16917677






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In the initial phase of pravastatin treatment (8 weeks), heterozygous carriers of the SLCO1B1*15 allele had poor low-density lipoprotein cholesterol (LDL-C) reduction relative to non-carriers (percent reduction: -14.1 vs -28.9%); however, the genotype-dependent difference in the cholesterol-lowering effect disappeared after 1 year of treatment. Cholesterol solute carrier organic anion transporter family member 1B1 Homo sapiens